http://www.bing.com:80/search?q=Masimo+Red+SpO2+Finger+ProbeSearch resultshttp://www.bing.com:80/s/a/rsslogo.gifhttp://www.bing.com:80/search?q=Masimo+Red+SpO2+Finger+ProbeCopyright © 2026 Microsoft. All rights reserved. These XML results may not be used, reproduced or transmitted in any manner or for any purpose other than rendering Bing results within an RSS aggregator for your personal, non-commercial use. Any other use of these results requires express written permission from Microsoft Corporation. By accessing this web page or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.https://www.masimo.com/Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, medical devices, and a wide array of sensors.Thu, 26 Mar 2026 09:00:00 GMThttps://www.masimo.com/technology/pulse-oximetry/Trusted by top hospitals around the world, industry-leading Masimo Signal Extraction Technology ® overcomes the limitations of conventional pulse oximetry to perform accurately and reliably during motion and low perfusion, across patient populations, and on all skin tones.Mon, 13 Apr 2026 05:11:00 GMThttps://www.masimo.com/company/about/Learn about Masimo’s mission, values, and breakthroughs in patient monitoring and medical technology, driving innovation and improving care worldwide.Sat, 11 Apr 2026 07:08:00 GMThttps://www.masimo.com/company/product-portfolio/Masimo is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, medical devices, and a wide array of sensors. We believe that Masimo SET® helps clinicians monitor in excess of approximately 100 million patients in healthcare settings around the world, and is the primary pulse oximetry technology at 17 of the top 20 hospitals ...Sun, 12 Apr 2026 13:12:00 GMThttps://www.masimo.com/monitoring-solutionsAdvanced Monitoring Solutions - Masimo’s first breakthrough technology, Signal Extraction Technology® (SET®), overcame the limitations of conventional pulse oximetry with the ability to measure through motion and low perfusion.Sat, 11 Apr 2026 10:00:00 GMThttps://investor.masimo.com/news/news-details/2026/Masimo-to-be-Acquired-by-Danaher-for-180-00-Per-Share/default.aspxMasimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) (“Danaher”) will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the “Transaction”). The Transaction has been unanimously approved by both ...Tue, 14 Apr 2026 07:04:00 GMThttps://www.masimo.com/contact-support/contact-us/Masimo Contact Us - We welcome your feedback! If you have a question, comment or concern, please complete the form below and we will respond within 2 business days.Sun, 12 Apr 2026 18:20:00 GMThttps://investor.masimo.com/news/news-details/2025/Masimo-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Updated-Full-Year-2025-Guidance/default.aspxMasimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full-year ended December 28, 2024 and provided updated estimates for its full-year 2025 guidance. Fourth Quarter 2024 Financial Results: Consolidated revenue was $601 million, representing 9% growth on a reported and constant currency basis (1) ; Healthcare revenue was $368 million, representing 8% growth on ...Tue, 14 Apr 2026 07:04:00 GMThttps://www.masimo.com/products/wearables/Masimo wearable devices provide freedom for patients and clinicians alike, eliminating physical connections without sacrificing the power of clinically proven Masimo continuous monitoring.Tue, 14 Apr 2026 01:28:00 GMThttps://investor.masimo.com/company-profile/default.aspxMasimo SET ® pulse oximetry has also been shown to improve patient outcomes by helping clinicians reduce retinopathy of prematurity (ROP) in neonates, screen newborns for critical congenital heart disease (CCHD), reduce ventilator weaning time and arterial blood gas measurements in the intensive care unit (ICU), and save lives and costs while ...Tue, 14 Apr 2026 18:32:00 GMT